HK1002901A1 - A composition used as a therapeutic agent against chronic viral hepatic diseases - Google Patents

A composition used as a therapeutic agent against chronic viral hepatic diseases

Info

Publication number
HK1002901A1
HK1002901A1 HK98101997A HK98101997A HK1002901A1 HK 1002901 A1 HK1002901 A1 HK 1002901A1 HK 98101997 A HK98101997 A HK 98101997A HK 98101997 A HK98101997 A HK 98101997A HK 1002901 A1 HK1002901 A1 HK 1002901A1
Authority
HK
Hong Kong
Prior art keywords
therapeutic agent
chronic viral
composition used
agent against
hepatic diseases
Prior art date
Application number
HK98101997A
Other languages
English (en)
Inventor
Hans A Thoma
Original Assignee
Medeva Holdings Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8204863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1002901(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medeva Holdings Bv filed Critical Medeva Holdings Bv
Publication of HK1002901A1 publication Critical patent/HK1002901A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK98101997A 1990-12-19 1998-03-10 A composition used as a therapeutic agent against chronic viral hepatic diseases HK1002901A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90124775A EP0491077A1 (en) 1990-12-19 1990-12-19 A composition used as a therapeutic agent against chronic viral hepatic diseases
PCT/EP1991/002460 WO1992011368A1 (en) 1990-12-19 1991-12-19 A composition used as a therapeutic agent against chronic viral hepatic diseases

Publications (1)

Publication Number Publication Date
HK1002901A1 true HK1002901A1 (en) 1998-09-25

Family

ID=8204863

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98101997A HK1002901A1 (en) 1990-12-19 1998-03-10 A composition used as a therapeutic agent against chronic viral hepatic diseases

Country Status (15)

Country Link
US (2) US6020167A (ko)
EP (2) EP0491077A1 (ko)
JP (2) JP3857305B2 (ko)
KR (1) KR0156587B1 (ko)
AT (1) ATE170220T1 (ko)
AU (1) AU657935B2 (ko)
CA (1) CA2098021C (ko)
CZ (1) CZ290233B6 (ko)
DE (1) DE69130071T3 (ko)
DK (1) DK0563093T4 (ko)
ES (1) ES2121000T5 (ko)
HK (1) HK1002901A1 (ko)
HU (1) HU216301B (ko)
SK (1) SK280551B6 (ko)
WO (1) WO1992011368A1 (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341074C (en) 1987-06-22 2000-08-08 Hans A. Thoma Hbv surface antigen particles, prepared by recombinant dna processes, composed of different epitopes, selected from the pre-s and s-peptides as a new vaccine
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
DE4107612A1 (de) 1991-03-09 1992-09-10 Behringwerke Ag Rekombinante proteine mit der immunreaktivitaet des hepatitis b virus e antigens (hbeag), verfahren zu ihrer herstellung und ihre verwendung in immunoassays und impfstoffen
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US6509149B2 (en) 1995-06-06 2003-01-21 Hybridon, Inc. HPV-specific oligonucleotides
WO1997049425A1 (en) * 1996-06-25 1997-12-31 Stichting Instituut Voor Dierhouderij En Diergezondheid Vaccine comprising antigens bound to carriers through labile bonds
US7091324B2 (en) 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
AU2001249564A1 (en) 2000-03-29 2001-10-08 Cornell Research Foundation Inc. Method of treating hepatitis delta viral infection
IL142802A (en) * 2000-04-27 2015-01-29 Enzo Therapeutics Inc Use of one or more HBV antigens for the preparation of oral pharmaceutical preparations for the treatment of a person with active HBV infection or hepatocellular carcinoma
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
WO2002062959A2 (en) * 2001-02-05 2002-08-15 Stressgen Biotechnologies Corp. Hepatitis b virus treatment
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
KR100708398B1 (ko) * 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
DE10339927A1 (de) * 2003-08-29 2005-03-24 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen
GB0326416D0 (en) 2003-11-12 2003-12-17 Karolinska Innovations Ab Methods and means relating to hepatitis B infection
CA2549865A1 (en) * 2003-11-12 2005-06-02 Hbv Theranostica Ab Methods and means relating to hepatitis b infection
EP1802746B1 (en) * 2004-10-27 2011-05-04 Crucell Switzerland AG Virosome particles comprising antigens from influenza virus and hepatitis b virus
EP2185195A2 (en) * 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
WO2009092396A1 (en) 2008-01-25 2009-07-30 Universitätsklinikum Heidelberg Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors
CN101485672B (zh) * 2008-12-05 2010-08-25 广东粤龙药业有限公司 异丙景糖酐在制备治疗人HBeAg阳性慢性乙型肝炎药物中的应用
US9393299B2 (en) 2009-08-07 2016-07-19 Transgene S.A. Composition for treating HBV infection
US10076570B2 (en) 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34705A (en) * 1862-03-18 Improvement in tompions for fire-arms
US3636191A (en) * 1969-10-08 1972-01-18 Cancer Res Inst Vaccine against viral hepatitis and process
FR2480779B2 (fr) * 1979-08-30 1986-07-18 Anvar Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur
EP0182442B2 (en) * 1978-12-22 1996-04-03 Biogen, Inc. Recombinant DNA molecules and their method of production
DD147855A5 (de) * 1978-12-22 1981-04-22 Biogen Nv Verfahren zur erzeugung mindestens eines hbv-antigenwirkung aufweisenden polypeptids
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
US4935235A (en) * 1979-05-24 1990-06-19 The Regents Of The University Of California Non-passageable viruses
US5196194A (en) * 1979-05-24 1993-03-23 The Regents Of The University Of California Vaccines containing Hepatitis B S-protein
USRE34705E (en) 1979-08-30 1994-08-23 Institut Pasteur Nucleotidic sequence coding the surface antigen of the hepatitis B virus, vector containing said nucleotidic sequence, process allowing the obtention thereof and antigen obtained thereby
US4415491A (en) * 1980-01-14 1983-11-15 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
EP0038765B1 (fr) * 1980-04-22 1987-09-02 Institut Pasteur Vaccin contre l'hépatite virale B, procédé et cellules eucaryotes transformées pour la production de ce vaccin
FI83662C (fi) * 1980-07-17 1991-08-12 Scripps Clinic Res Diagnostik antikropp och foerfarande foer dess framstaellning.
GR76274B (ko) * 1981-08-04 1984-08-04 Univ California
AU8746582A (en) * 1981-09-02 1983-03-10 Biogen N.V. Hepatitis b virus e type antigen
US4741901A (en) * 1981-12-03 1988-05-03 Genentech, Inc. Preparation of polypeptides in vertebrate cell culture
JPS58194897A (ja) * 1982-05-07 1983-11-12 Takeda Chem Ind Ltd 新規ｄｎａ，その製造方法およびそれで形質転換させた宿主
JPS5936698A (ja) * 1982-08-20 1984-02-28 Science & Tech Agency Ｂ型肝炎ウイルス遺伝子を組込んだ組換えｄｎａおよび形質転換動物細胞
US4977092A (en) * 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US5198348A (en) * 1982-08-30 1993-03-30 Amgen Inc. Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
JPS5974985A (ja) * 1982-10-19 1984-04-27 Takeda Chem Ind Ltd 新規ｄｎａ
CA1341116C (en) * 1983-02-22 2000-10-17 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis or foreign protein
US4696898A (en) * 1984-01-16 1987-09-29 Integrated Genetics, Inc. Vector encoding hepatitis B surface antigen
FR2559159B1 (fr) * 1984-02-02 1986-09-12 Inst Nat Sante Rech Med Vecteurs viraux de clonage et d'expression d'une proteine dans une cellule eucaryote, comportant au moins une partie du genome d'un retro-virus; cellules eucaryotes transfectees; procede utilisant de telles cellules et proteines obtenues
FR2560890B1 (fr) * 1984-03-07 1987-10-16 Grp Genie Genetique Composition utile pour la fabrication de vaccins contenant des particules portant l'antigene de surface du virus de l'hepatite b et le recepteur de l'albumine serique humaine polymerisee, cellules animales capables de produire de telles particules et procede pour leur obtention
US5324513A (en) * 1984-03-07 1994-06-28 Institut Pasteur Composition useful for the fabrication of vaccines
US5204096A (en) * 1984-03-07 1993-04-20 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US4861588A (en) * 1985-02-05 1989-08-29 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US4847080A (en) * 1984-03-07 1989-07-11 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers
US5158769A (en) * 1984-03-07 1992-10-27 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US4777240A (en) * 1984-03-08 1988-10-11 Scripps Clinic And Research Foundation SV40 expression vector containing HBxAg as an expression marker
US4942125A (en) * 1984-09-07 1990-07-17 Scripps Clinic And Research Foundation SV40 expression vector containing HBxAg as an expression marker
AU579148B2 (en) * 1984-03-09 1988-11-17 Scripps Clinic And Research Foundation Synthetic hepatitis b virus vaccine including both t cell and b cell determinants
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US5098704A (en) * 1984-06-18 1992-03-24 Chiron Corporation Hepatitis surface antigen particle vaccine
EP0401941A3 (en) * 1984-07-11 1991-04-17 Takeda Chemical Industries, Ltd. Hepatitis b virus surface antigen and production thereof
GB8421282D0 (en) * 1984-08-22 1984-09-26 Connaught Lab Multispecific antigenic proteins
US4722940A (en) * 1984-08-23 1988-02-02 Georgia Tech Research Corporation Aminoalkyl phenyl selenides for the treatment of hypertension and nervous system dysfunctions
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
ATE70308T1 (de) * 1984-09-12 1991-12-15 Chiron Corp Hybridpartikel-immunogene.
US4639371A (en) * 1984-10-02 1987-01-27 New York Blood Center, Inc. Hepatitis B antigenic compositions and vaccines against hepatitis B derived therefrom
EP0180012A1 (de) * 1984-10-27 1986-05-07 Wolfram H. Prof. Dr. Gerlich Immunogene Polypeptidsequenz des Hepatitis B-Virus
US4683136A (en) * 1985-03-06 1987-07-28 Scripps Clinic And Research Foundation Proteinaceous antigens with conformation-independent and conformation-dependent determinants
CA1324094C (en) * 1985-04-03 1993-11-09 Dino Dina Hepatitis a virus vaccines
FI861417A0 (fi) * 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US5837249A (en) * 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US4639271A (en) * 1985-04-24 1987-01-27 Moore Business Forms, Inc. Chromogenic mixtures
FR2581394B1 (fr) * 1985-05-02 1988-08-05 Grp Genie Genetique Particules ayant les proprietes immunogenes de l'antigene hbs et portant un site antigenique etranger aux epitopes portes par l'antigene hbs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
JPH084507B2 (ja) * 1985-10-03 1996-01-24 武田薬品工業株式会社 新規ｄｎａおよびポリペプチド
US4959323A (en) * 1985-11-04 1990-09-25 Mt. Sinai School Of Medicine Of The City University Of New York Production and use of pre S polypeptides of hepatitis B virus
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
US4742158A (en) * 1986-04-25 1988-05-03 Merck & Co., Inc. Purification of hepatitis pre-S antigens by polymerized serum albumin affinity binding
IE59389B1 (en) * 1986-05-23 1994-12-23 Merck & Co Inc Method for producing hepatitis b virus core antigen (HBcAg) in yeast
CA1310602C (en) * 1986-06-03 1992-11-24 Hajime Horii Yeast promoter and process for preparing heterologous protein
AU617292B2 (en) * 1986-06-20 1991-11-28 Scripps Clinic And Research Foundation T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen
US5068185A (en) * 1986-07-10 1991-11-26 Merck & Co., Inc. Trains of yeast for the expression of heterologous genes
IL79740A0 (en) * 1986-08-17 1986-11-30 Yeda Res & Dev Hepatitis vaccine
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
AP56A (en) * 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
CA1341074C (en) * 1987-06-22 2000-08-08 Hans A. Thoma Hbv surface antigen particles, prepared by recombinant dna processes, composed of different epitopes, selected from the pre-s and s-peptides as a new vaccine
EP1088830A3 (en) * 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
US4883865A (en) * 1987-09-30 1989-11-28 Merck & Co. Inc. Recovery of pres2+s antigen
US4963483A (en) * 1987-10-13 1990-10-16 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
US5011915A (en) * 1987-10-26 1991-04-30 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
US5039522A (en) * 1988-01-29 1991-08-13 New York Blood Center, Inc. Immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen
NZ229260A (en) * 1988-06-03 1994-02-25 Merck & Co Inc Hepatitis b virus, expression cassette for pre-s domain, host cells and
US5242812A (en) * 1989-02-07 1993-09-07 Bio-Technology General Corp. Method for production and purification of hepatitis B vaccine
US5462863A (en) * 1989-02-09 1995-10-31 Development Center For Biotechnology Isolation of Hepatitis B surface antigen from transformed yeast cells
GB8903313D0 (en) * 1989-02-14 1989-04-05 Wellcome Found Conjugates
ES2109921T3 (es) * 1989-07-25 1998-02-01 Smithkline Beecham Biolog Nuevos antigenos y procedimientos para su preparacion.
EP0421626A1 (en) * 1989-09-19 1991-04-10 Merck & Co. Inc. Vaccine for aids and hepatitis B
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
US5102989A (en) * 1991-03-15 1992-04-07 Merck & Co., Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from recombinant host cells
IL101653A0 (en) * 1991-04-29 1992-12-30 Merck & Co Inc Multiple hepatitis b virus surface proteins which form particles
CA2067003A1 (en) * 1991-04-29 1992-10-30 Peter J. Kniskern Hbsag escape mutant vaccine
US5840303A (en) * 1991-08-26 1998-11-24 The Scripps Research Foundation Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
JP2501186Y2 (ja) * 1992-03-31 1996-06-12 株式会社栗本鐵工所 ハンマ―ミル
CN1063343C (zh) * 1993-04-27 2001-03-21 中国科学院上海生物化学研究所 氨端带前表面抗原决定簇的乙型肝炎表面抗原蛋白
CN1094311A (zh) * 1993-04-27 1994-11-02 中国科学院上海生物化学研究所 氨端带前表面抗原决定簇的乙型肝炎表面抗原蛋白
CN1059927C (zh) * 1994-03-10 2000-12-27 中国科学院上海生物化学研究所 羧端带有前表面抗原1抗原决定簇的乙肝表面抗原融合基因及其编码蛋白
US5792163A (en) * 1996-01-03 1998-08-11 Hitzig; Gary Linear punch

Also Published As

Publication number Publication date
AU657935B2 (en) 1995-03-30
AU9081791A (en) 1992-07-22
JPH06507303A (ja) 1994-08-25
JP3857305B2 (ja) 2006-12-13
ATE170220T1 (de) 1998-09-15
ES2121000T5 (es) 2008-04-16
EP0491077A1 (en) 1992-06-24
WO1992011368A1 (en) 1992-07-09
HUT66437A (en) 1994-11-28
KR0156587B1 (en) 1998-10-15
EP0563093B1 (en) 1998-08-26
JP2001019643A (ja) 2001-01-23
EP0563093A1 (en) 1993-10-06
DE69130071T3 (de) 2008-02-21
DE69130071T2 (de) 1999-01-07
DE69130071D1 (de) 1998-10-01
EP0563093B2 (en) 2007-10-03
CZ118693A3 (en) 1994-02-16
US6020167A (en) 2000-02-01
DK0563093T4 (da) 2008-01-21
CA2098021C (en) 2000-04-25
CZ290233B6 (cs) 2002-06-12
US20030235591A1 (en) 2003-12-25
SK63693A3 (en) 1993-10-06
DK0563093T3 (da) 1999-02-08
CA2098021A1 (en) 1992-06-20
HU9301794D0 (en) 1993-10-28
HU216301B (hu) 1999-06-28
SK280551B6 (sk) 2000-03-13
ES2121000T3 (es) 1998-11-16

Similar Documents

Publication Publication Date Title
HUT66437A (en) A composition used as a therapeutic agent against chronic viral hepatic diseases
PT725824E (pt) Epitopos de celulas t humanas imunodominantes do virus da hepatite c
TW249226B (ko)
EP0230575A3 (de) Arzneimittel mit Antitumorwirkung das Hexadecylphosphocholin enthält
GR3020902T3 (en) Use of 15-keto-prostaglandin compound for improvement of encephalic function
NO902411D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-hydroksy-n-propylaminer.
EP0273277A3 (en) Pharmaceutical composition comprising 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) in treating patients infected with retrovirus
EP0455448A3 (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
NO995944L (no) Anti-arrytmisk blanding og fremgangsmåter for behandling
GR3018674T3 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
JPS529087A (en) Blood-compatible high-polymeric materials for medical use
EP0430551A3 (en) Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
EP0430552A3 (en) Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
CS318690A3 (en) Pharmaceutical composition usable for depression therapy
IL98200A0 (en) Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
AU2715288A (en) Human respiratory syncytialvirus vaccine derived from the 1a (9.5 kd) protein
EP0505608A3 (en) Alpha-dihydroergocryptine pharmaceutical preparations with neuroprotective acitivity
ATE64855T1 (de) Zubereitungen und verfahren zum schutz von tlymphozyten gegen das krankheitsagens von lymphadenopathie und vom erworbenen immundepressionsyndrom.
MXPA94003453A (es) Metodo y composicion para el tratamiento de pacientes con hepatitis b que tienen descompensacion hepatica.
ATE72948T1 (de) Schutzmaske fuer medizinische zwecke, insbesondere fuer chirurgen.
IT208775Z2 (it) Siringa per l'anestesia intraligamentosa.
IT9003745A0 (it) Ago a farfalla di sicurezza per uso medicale.
HUT63771A (en) Living virus containing stabilized therapeutic composition against viral diseases and malignant tumours, as well as process for producing same
ES8706441A1 (es) Procedimiento para preparar una composicion farmaceutica a base de sulpirida y un progestageno.

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20081219